Evaluation of physcion isolated from endophytic Aspergillus fumigatus ASH3 as an antiviral agent against coxsackievirus B4 and herpes simplex virus type 1: in silico-supported in vitro study

Key Points

• Physcion demonstrates notable antiviral effects on both coxsackievirus B4 and herpes simplex virus 1, indicating its therapeutic potential.
• The study highlights a significant reduction of viral activity by up to 70% with physcion treatment.
• In silico-supported in vitro analysis utilizes advanced modeling techniques to predict antiviral activity.
• The findings suggest the need for further clinical evaluation to establish the efficacy and safety of physcion-based therapies.